Business
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
-- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 -- --
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"-- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 --\n -- PTG-300 received European Medicine Agency (EMA) Orphan Drug Designation for the treatment of polycythemia vera --\n -- Company is advancing additional oral IL-23 receptor antagonists into clinical development in collaboration with Janssen --\n\n\nNEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate update.\n\n \n \n \n \n \n \n\n \n\"The three clinical assets PTG-300, PN-943 and PTG-200, all discovered through our peptide technology platform, continue to make progress in Phase 2 clinical proof-of-concept studies,\" commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer. \"We look forward to sharing updated clinical data in December from our Phase 2 study of PTG-300 in patients with polycythemia vera and see significant opportunity for PTG-300 to address unmet needs and improve upon the current standards of care.\"\nDr. Patel continued, \"We are moving forward with our ongoing Phase 2 clinical programs with the oral alpha-4-beta-7 integrin antagonist PN-943 in patients with ulcerative colitis, and the oral interleukin-23 receptor antagonist PTG-200 in patients with Crohn's disease. In addition, we're encouraged by the steady progress in our ongoing collaboration with Janssen, and recently announced the selection of two additional oral interleukin-23 receptor antagonists, PN-235 and PN-232, for advancement into clinical development. These candidates provide several strategic options for development in multiple indications.\"\nProduct Development and Corporate Update\nPTG-300: Subcutaneous Injectable Hepcidin Mimetic for Polycythemia Vera and Other Blood Disorders\nFive presentations have been accepted for the American Society for Hematology (ASH) Annual meeting, taking place in a virtual format from December 5-8, 2020. Two posters and one oral presentation are related to PTG-300 and polycythemia vera and two posters describe the hepcidin mimetic mechanism of action and a hepcidin mimetic for oral delivery. In October, PTG-300 was granted orphan designation by the European Medicines Agency for the trea...